Emerald Mutual Fund Advisers Trust Sells 101,292 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Emerald Mutual Fund Advisers Trust reduced its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 15.6% during the fourth quarter, HoldingsChannel reports. The fund owned 549,688 shares of the specialty pharmaceutical company’s stock after selling 101,292 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in KalVista Pharmaceuticals were worth $4,656,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Schroder Investment Management Group grew its holdings in KalVista Pharmaceuticals by 86.8% during the 4th quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company’s stock valued at $6,758,000 after buying an additional 374,213 shares in the last quarter. Walleye Capital LLC purchased a new stake in KalVista Pharmaceuticals in the 4th quarter worth approximately $2,268,000. Vanguard Group Inc. raised its position in KalVista Pharmaceuticals by 4.9% during the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock valued at $19,102,000 after purchasing an additional 104,716 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of KalVista Pharmaceuticals by 691.5% in the 4th quarter. Marshall Wace LLP now owns 117,978 shares of the specialty pharmaceutical company’s stock worth $999,000 after purchasing an additional 103,072 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of KalVista Pharmaceuticals by 14.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 696,037 shares of the specialty pharmaceutical company’s stock valued at $5,895,000 after purchasing an additional 89,001 shares during the last quarter.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, major shareholder Venrock Healthcare Capital Par bought 25,000 shares of the company’s stock in a transaction on Wednesday, April 9th. The shares were acquired at an average cost of $9.42 per share, with a total value of $235,500.00. Following the completion of the transaction, the insider now owns 5,303,985 shares of the company’s stock, valued at approximately $49,963,538.70. This trade represents a 0.47 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the sale, the chief executive officer now directly owns 278,855 shares of the company’s stock, valued at $2,738,356.10. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 261,055 shares of company stock worth $2,397,646 and sold 17,292 shares worth $184,625. 10.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on KALV. TD Cowen started coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Jones Trading reaffirmed a “buy” rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $24.83.

KalVista Pharmaceuticals Trading Up 0.1 %

Shares of KALV stock opened at $13.00 on Tuesday. The stock has a market cap of $646.31 million, a PE ratio of -3.57 and a beta of 0.39. The company’s fifty day moving average price is $11.66 and its 200-day moving average price is $10.36. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).